The study will characterize the biology of FMT in the context of IBS prior to wider clinical application of the method. Given the ethical concerns of unknown and long-term adverse effects of FMT therapy, the study will include patients only with moderate to severe symptoms. IBS is a heterogenous disorder and it is important to characterize the patients, and study as homogeneous patient populations as possible. Therefore the study will only include post-infectious IBS patients after the Giardia outbreak.
Primary aims: Detailed characterisation of donor and recipient microbial community composition (by means of 16S rRNA profiling) and determination of the kinetics of changes following FMT Secondary aims: * Determination of interactions of importance to persisting recipient gut microbiota. * Evaluate safety of FMT in an IBS population * To evaluate the efficacy of FMT in relieving symptoms in selected patients with IBS in an open pilot trial in order to have the possibility to calculate number of patients needed when planning future controlled studies.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
14
helathy donor fecal suspension administered by duodenal scope
Helse Bergen HF, Haukeland University Hospital
Bergen, Norway
Stool microbiota changes
abundance of major microbial taxa in fecal transplant post transplantation
Time frame: up to 28 weeks
Global improvement in IBS symptoms
Patient questionnaires IBSS-S
Time frame: up to 28 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.